El Suplemento, the organizer of Premios Tecnológia Siglo XXI 2018, has awarded SOM Biotech in the Hito Tecnológico (Technological Milestone) category for the company's commitment to achieve medical advances for the benefit of different orphan diseases, and for its exponential growth during the past year. SOM Biotech CEO, Dr. Raúl Insa, received the award at the Gala held in Madrid on February 15th…
SOM Biotech wins Premio Hito Tecnológico
posted on February 22, 2018
SOM Biotech joins in raising awareness of rare diseases
posted on February 19, 2018
To show its support for raising public awareness of rare diseases, SOM Biotech joins the Rare Disease Day 2018 campaign by painting faces, taking pictures and sharing them on various social media platforms. Not only does the campaign promote rare disease awareness, but also fosters fellowship among the team members. #ShowYourRare Rare Disease Day is the international awareness-raising campaign for…
World Rare Disease Day 2018
posted on January 26, 2018
Since 2008, World Rare Disease Day is celebrated on the last day of February each year. This event aims to raise public awareness of rare diseases and promote engagement among patients, associations, researchers , decision-makers and other stakeholders. SOM Biotech, a private pharmaceutical company focused on drug repurposing for neurological rare diseases, will join in…
SOM Biotech at Biotech & Money Congress 2018
posted on January 26, 2018
SOM Biotech CEO, Dr. Raúl Insa, will attend the Biotech & Money Congress in London on 5th-7th of February. Dr. Insa will have the opportunity to present the company at the event and meet prospective investors and notable people in the industry. If you want to arrange a meeting with Dr. Insa, send an email…
Duchenne Parent Project España y SOM Biotech renuevan su acuerdo de colaboración
posted on January 24, 2018
Tras los resultados obtenidos durante el primer año de colaboración, la Asociación Duchenne Parent Project España (DPPE) confía nuevamente en la compañía Biofarmacéutica SOM Biotech prolongando el acuerdo de colaboración para llevar a cabo el proyecto “Reposicionamiento de Fármacos para la Distrofia Muscular de Duchenne (DMD)”. El equipo de SOM Biotech ha concluido satisfactoriamente la…
2017: A landmark year for SOM Biotech
posted on December 19, 2017
As 2017 comes to a close, it is a great time of year for business to reflect on the achievements and the short comings versus the goals set out at the beginning of the year. This year has been a landmark year for SOM Biotech, shifting gear from an early stage company to growth phase…